{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:41:38Z","timestamp":1791999698806,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"DOI":"10.7759\/cureus.105114","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:55:04Z","timestamp":1773334504000},"source":"Crossref","is-referenced-by-count":2,"title":["Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights"],"prefix":"10.7759","author":[{"given":"Raghad","family":"Abdelfadil Elgazzar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2022.03.009","article-title":"SGLT2 inhibitors in type 2 diabetes mellitus","volume":"18","author":"Ferrannini G","year":"2022","unstructured":"Ferrannini G, Savarese G, Cosentino F. SGLT2 inhibitors in type 2 diabetes mellitus. Heart Fail Clin. 2022, 18:551-9. 10.1016\/j.hfc.2022.03.009","journal-title":"Heart Fail Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey CJ","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:39-52. 10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon V","year":"2024","unstructured":"Vallon V. State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024, 37:841-52. 10.1093\/ajh\/hpae092","journal-title":"Am J Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","article-title":"Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes","volume":"33","author":"Benham JL","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021, 33:100725. 10.1016\/j.ijcha.2021.100725","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis","volume":"36","author":"Cardoso R","year":"2021","unstructured":"Cardoso R, Graffunder FP, Ternes CM, Fernandes A, Rocha AV, Fernandes G, Bhatt DL. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021, 36:100933. 10.1016\/j.eclinm.2021.100933","journal-title":"EClinicalMedicine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly E","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, et al.. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022, 65:2000-10. 10.1007\/s00125-022-05773-8","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02042-9","article-title":"Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis","volume":"23","author":"Chen J","year":"2024","unstructured":"Chen J, Jiang C, Guo M, et al.. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024, 23:2. 10.1186\/s12933-023-02042-9","journal-title":"Cardiovasc Diabetol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx N","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44:4043-140. 10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"ref9","unstructured":"Use of SGLT2 inhibitors in the management of patients with heart failure. pocket guide. (2024). Accessed: March 1, 2026: https:\/\/www.acc.org\/-\/media\/Non-Clinical\/Files-PDFs-Excel-MS-Word-etc\/Tools-and-Practice-Support\/Clinical-Solutions\/B...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas TA","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023, 13:15922. 10.1038\/s41598-023-42989-z","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze AD","year":"2022","unstructured":"Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol. 2022, 21:47. 10.1186\/s12933-022-01476-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02690320","article-title":"Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease","volume":"15","author":"Li J","year":"2020","unstructured":"Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020, 15:1678-88. 10.2215\/CJN.02690320","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022, 102:974-89. 10.1016\/j.kint.2022.08.012","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.12.013","article-title":"Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction","volume":"99","author":"Juni RP","year":"2021","unstructured":"Juni RP, Al-Shama R, Kuster DW, et al.. Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney Int. 2021, 99:1088-101. 10.1016\/j.kint.2020.12.013","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115863","article-title":"Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects","volume":"22","author":"Palmiero G","year":"2021","unstructured":"Palmiero G, Cesaro A, Vetrano E, et al.. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021, 22:5863. 10.3390\/ijms22115863","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad345","article-title":"SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?","volume":"44","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Testani JM. SGLT2 inhibitors and diuretics in heart failure: clicking reset on the renal volume setpoint?. Eur Heart J. 2023, 44:2944-6. 10.1093\/eurheartj\/ehad345","journal-title":"Eur Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi A","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, et al.. A role for tubular Na(+)\/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol. 2020, 319:F712-28. 10.1152\/ajprenal.00264.2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen R","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC, et al.. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019, 139:2129-41. 10.1161\/CIRCULATIONAHA.118.036459","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos TD","year":"2019","unstructured":"Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019, 131:82-8. 10.1080\/00325481.2019.1581971","journal-title":"Postgrad Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego CG","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al.. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019, 73:1931-44. 10.1016\/j.jacc.2019.01.056","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai C","year":"2022","unstructured":"Cai C, Guo Z, Chang X, et al.. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022, 52:102288. 10.1016\/j.redox.2022.102288","journal-title":"Redox Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda A","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, L\u00fcscher TF, Kraler S, Liberale L. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024, 120:443-60. 10.1093\/cvr\/cvae047","journal-title":"Cardiovasc Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco C","year":"2024","unstructured":"Luna-Marco C, Iannantuoni F, Hermo-Argibay A, Devos D, Salazar JD, V\u00edctor VM, Rovira-Llopis S. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radic Biol Med. 2024, 213:19-35. 10.1016\/j.freeradbiomed.2024.01.015","journal-title":"Free Radic Biol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925276","article-title":"Dapagliflozin protects methamphetamine-induced cardiomyopathy by alleviating mitochondrial damage and reducing cardiac function decline in a mouse model","volume":"13","author":"He S","year":"2022","unstructured":"He S, Yao Y, Yang N, et al.. Dapagliflozin protects methamphetamine-induced cardiomyopathy by alleviating mitochondrial damage and reducing cardiac function decline in a mouse model. Front Pharmacol. 2022, 13:925276. 10.3389\/fphar.2022.925276","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li C","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al.. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019, 18:15. 10.1186\/s12933-019-0816-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010137","article-title":"Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches","volume":"11","author":"Xu J","year":"2021","unstructured":"Xu J, Hirai T, Koya D, Kitada M. Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches. J Clin Med. 2021, 11:137. 10.3390\/jcm11010137","journal-title":"J Clin Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Del Buono MG","year":"2021","unstructured":"Del Buono MG, Montone RA, Camilli M, et al.. Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review. J Am Coll Cardiol. 2021, 78:1352-71. 10.1016\/j.jacc.2021.07.042","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer M","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022, 146:1383-405. 10.1161\/CIRCULATIONAHA.122.061732","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian J","year":"2021","unstructured":"Tian J, Zhang M, Suo M, et al.. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021, 25:7642-59. 10.1111\/jcmm.16601","journal-title":"J Cell Mol Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07083-w","article-title":"Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells","volume":"35","author":"Uthman L","year":"2021","unstructured":"Uthman L, Kuschma M, R\u00f6mer G, et al.. Novel anti-inflammatory effects of canagliflozin involving hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther. 2021, 35:1083-94. 10.1007\/s10557-020-07083-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14233","article-title":"Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence","volume":"24","author":"Khemais-Benkhiat S","year":"2020","unstructured":"Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, et al.. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med. 2020, 24:2109-22. 10.1111\/jcmm.14233","journal-title":"J Cell Mol Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165770","article-title":"SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models","volume":"1866","author":"Andreadou I","year":"2020","unstructured":"Andreadou I, Bell RM, B\u00f8tker HE, Zuurbier CJ. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis. 2020, 1866:165770. 10.1016\/j.bbadis.2020.165770","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz072","article-title":"Shining the spotlight on cardioprotection: beyond the cardiomyocyte","volume":"115","author":"Davidson SM","year":"2019","unstructured":"Davidson SM, Andreadou I, Garcia-Dorado D, Hausenloy DJ. Shining the spotlight on cardioprotection: beyond the cardiomyocyte. Cardiovasc Res. 2019, 115:1115-16. 10.1093\/cvr\/cvz072","journal-title":"Cardiovasc Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa857","article-title":"Assessment and pathophysiology of microvascular disease: recent progress and clinical implications","volume":"42","author":"Masi S","year":"2021","unstructured":"Masi S, Rizzoni D, Taddei S, et al.. Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. Eur Heart J. 2021, 42:2590-604. 10.1093\/eurheartj\/ehaa857","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang K","year":"2022","unstructured":"Jiang K, Xu Y, Wang D, et al.. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022, 13:336-59. 10.1007\/s13238-020-00809-4","journal-title":"Protein Cell"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen S","year":"2023","unstructured":"Chen S, Wang Q, Christodoulou A, et al.. Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation. 2023, 147:276-9. 10.1161\/CIRCULATIONAHA.122.061688","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox CS","year":"2020","unstructured":"Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020, 75:894-901. 10.1161\/HYPERTENSIONAHA.119.11684","journal-title":"Hypertension"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13094","article-title":"Proximal tubule-specific deletion of the NHE3 (NA(+)\/H(+) exchanger 3) in the kidney attenuates Ang II (angiotensin II)-induced hypertension in mice","volume":"74","author":"Li XC","year":"2019","unstructured":"Li XC, Zhu D, Chen X, et al.. Proximal tubule-specific deletion of the NHE3 (NA(+)\/H(+) exchanger 3) in the kidney attenuates Ang II (angiotensin II)-induced hypertension in mice. Hypertension. 2019, 74:526-35. 10.1161\/HYPERTENSIONAHA.119.13094","journal-title":"Hypertension"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer M","year":"2023","unstructured":"Packer M. Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure. Cardiovasc Diabetol. 2023, 22:197. 10.1186\/s12933-023-01946-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020279","article-title":"SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease","volume":"11","author":"Podest\u00e0 MA","year":"2023","unstructured":"Podest\u00e0 MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023, 11:279. 10.3390\/biomedicines11020279","journal-title":"Biomedicines"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink HJ","year":"2019","unstructured":"Heerspink HJ, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019, 62:1154-66. 10.1007\/s00125-019-4859-4","journal-title":"Diabetologia"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett D","year":"2021","unstructured":"Fitchett D, Inzucchi SE, Zinman B, et al.. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021, 8:4517-27. 10.1002\/ehf2.13615","journal-title":"ESC Heart Fail"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li J","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, et al.. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020, 8:57-66. 10.1016\/j.jchf.2019.08.004","journal-title":"JACC Heart Fail"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski D","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, et al.. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022, 43:4421-32. 10.1093\/eurheartj\/ehac494","journal-title":"Eur Heart J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James S","year":"2024","unstructured":"James S, Erlinge D, Storey RF, et al.. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024, 3:EVIDoa2300286. 10.1056\/EVIDoa2300286","journal-title":"NEJM Evid"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu M","year":"2021","unstructured":"Qiu M, Ding LL, Zhang M, Zhou HR. Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res. 2021, 18:14791641211011016. 10.1177\/14791641211011016","journal-title":"Diab Vasc Dis Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis","volume":"7","author":"Butler J","year":"2020","unstructured":"Butler J, Usman MS, Khan MS, et al.. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020, 7:3298-309. 10.1002\/ehf2.13169","journal-title":"ESC Heart Fail"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1177\/11795468251347777","article-title":"Evaluating the safety and efficacy of SGLT-2 inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92,920 patients","volume":"19","author":"Haider SH","year":"2025","unstructured":"Haider SH, Irfan A, Sheikh SM, Larik MO, Raza A, Khabir Y. Evaluating the safety and efficacy of SGLT-2 inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92,920 patients. Clin Med Insights Cardiol. 2025, 19:11795468251347777. 10.1177\/11795468251347777","journal-title":"Clin Med Insights Cardiol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells","volume":"23","author":"Alsereidi FR","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, et al.. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells. Cardiovasc Diabetol. 2024, 23:388. 10.1186\/s12933-024-02481-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102524","article-title":"Targeting inflammatory signaling pathways with SGLT2 inhibitors: insights into cardiovascular health and cardiac cell improvement","volume":"49","author":"Alsereidi FR","year":"2024","unstructured":"Alsereidi FR, Khashim Z, Marzook H, Gupta A, Al-Rawi AM, Ramadan MM, Saleh MA. Targeting inflammatory signaling pathways with SGLT2 inhibitors: insights into cardiovascular health and cardiac cell improvement. Curr Probl Cardiol. 2024, 49:102524. 10.1016\/j.cpcardiol.2024.102524","journal-title":"Curr Probl Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne KJ","year":"2025","unstructured":"Mayne KJ, Sardell RJ, Staplin N, et al.. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2025, 40:720-30. 10.1093\/ndt\/gfae203","journal-title":"Nephrol Dial Transplant"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow GM","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N, et al.. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021, 32:2352-61. 10.1681\/ASN.2021020167","journal-title":"J Am Soc Nephrol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.728089","article-title":"Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis","volume":"8","author":"Li N","year":"2021","unstructured":"Li N, Lv D, Zhu X, et al.. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med (Lausanne). 2021, 8:728089. 10.3389\/fmed.2021.728089","journal-title":"Front Med (Lausanne)"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96689","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in atrial fibrillation: clinical implications, mechanisms, and therapeutic potential","volume":"17","author":"Ramadan MM","year":"2025","unstructured":"Ramadan MM, Jawish MK, Tamim O, et al.. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in atrial fibrillation: clinical implications, mechanisms, and therapeutic potential. Cureus. 2025, 17:e96689. 10.7759\/cureus.96689","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473157-sodium-glucose-cotransporter-2-inhibitors-across-the-glycemic-spectrum-cardiovascular-and-renal-outcomes-with-mechanistic-insights","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:55:09Z","timestamp":1773334509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473157-sodium-glucose-cotransporter-2-inhibitors-across-the-glycemic-spectrum-cardiovascular-and-renal-outcomes-with-mechanistic-insights"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":65,"URL":"https:\/\/doi.org\/10.7759\/cureus.105114","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}